<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876927</url>
  </required_header>
  <id_info>
    <org_study_id>IRST151.01</org_study_id>
    <secondary_id>2010-020189-37</secondary_id>
    <nct_id>NCT01876927</nct_id>
  </id_info>
  <brief_title>Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer</brief_title>
  <acronym>GastroDOC</acronym>
  <official_title>A Randomised Phase Ii Study Of Pre-Operative Or Peri-Operative Docetaxel, Oxaliplatin, Capecitabine (Dox) Regimen In Patients With Locally Advanced Resectable Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design:&#xD;
&#xD;
      Multicenter, randomized, open label phase II study Arm A: DOX 4 cycles - Surgery - Follow-up&#xD;
      Arm B: DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Male or female, 18-75 years of age, with a diagnosis of histologically confirmed, potentially&#xD;
      resectable adenocarcinoma of the stomach.&#xD;
&#xD;
      Sample Size: Planned sample size is 90 patients, 45 patients for each arm (p0=50%, p1=80%,&#xD;
      alpha=0.05 (two sides), beta=0.2)&#xD;
&#xD;
      Treatment Plan:&#xD;
&#xD;
      Treatment will be administered for 4 and 2 cycles before surgery in arm A and B,&#xD;
      respectively, and in arm B for a further 2 cycles after surgery unless progression or&#xD;
      unacceptable toxicity occurs, or a patient refuses treatment. In such cases patients will go&#xD;
      off treatment. 3-6 weeks after the end of the fourth (arm A) or second (arm B) preoperative&#xD;
      cycle, patients will undergo surgery.&#xD;
&#xD;
      After surgery 3-6 weeks from surgery patients in arm B will receive 2 more cycles.&#xD;
&#xD;
      DOX: Docetaxel 35 mg/m2 day 1 and 8 Oxaliplatin 80 mg/m2 day 1 Capecitabine 750 mg/m2 x 2&#xD;
      daily for 2 weeks&#xD;
&#xD;
      Cycles repeated every 3 weeks&#xD;
&#xD;
      Evaluation criteria: Tumor assessment will be performed according to the RECIST criteria&#xD;
      (version 1.1).&#xD;
&#xD;
      Duration of Study:&#xD;
&#xD;
      Overall study duration: 07/2010- 03/2017 Planned study duration per patient: 5 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: A randomised phase II study of pre-operative or peri-operative docetaxel, oxaliplatin,&#xD;
      capecitabine (DOX) regimen in patients with locally advanced resectable gastric cancer.&#xD;
&#xD;
      Clinical Phase: II&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      The percentage of patients receiving all the planned chemotherapeutic cycles.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Downstaging according to Recist criteria&#xD;
&#xD;
        -  pT1-3 vs pT0.&#xD;
&#xD;
        -  Safety: number of patients with grade 3-4 toxicity&#xD;
&#xD;
        -  The role of PET Scan as predictor of response&#xD;
&#xD;
        -  Curative vs palliative surgery&#xD;
&#xD;
        -  TTP&#xD;
&#xD;
        -  OS&#xD;
&#xD;
        -  Diagnostic correlation between the various staging methods&#xD;
&#xD;
        -  Possible correlations between CT scan, CT/PET, laparoscopy;&#xD;
&#xD;
        -  Molecular markers related to toxicity: DPYD, MTHFR, TS, XPD, ERCC1, XRCC1;&#xD;
&#xD;
        -  Molecular markers related to prognosis: TYMS, GSTP1, COX-2, RUNX3, methylation profile&#xD;
           (Cox2, hMLH1, MGMT);&#xD;
&#xD;
        -  Molecular markers related to therapy response: TYMS, DPYD, MTHFR, OPRT, ERCC1,&#xD;
           XRCC1/2/3, GSTP1, GSTM1, GSTT1, ABCB1, methylation profile (Cox2, hMLH1, MGMT), whole&#xD;
           genome arrayCGH.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Multicenter, randomized, open label phase II study Arm A: DOX 4 cycles - Surgery - Follow-up&#xD;
      Arm B: DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Male or female, 18-75 years of age, with a diagnosis of histologically confirmed, potentially&#xD;
      resectable adenocarcinoma of the stomach.&#xD;
&#xD;
      Sample Size: Planned sample size is 90 patients, 45 patients for each arm (p0=50%, p1=80%,&#xD;
      alpha=0.05 (two sides), beta=0.2)&#xD;
&#xD;
      Treatment Plan:&#xD;
&#xD;
      Treatment will be administered for 4 and 2 cycles before surgery in arm A and B,&#xD;
      respectively, and in arm B for a further 2 cycles after surgery unless progression or&#xD;
      unacceptable toxicity occurs, or a patient refuses treatment. In such cases patients will go&#xD;
      off treatment. 3-6 weeks after the end of the fourth (arm A) or second (arm B) preoperative&#xD;
      cycle, patients will undergo surgery.&#xD;
&#xD;
      After surgery 3-6 weeks from surgery patients in arm B will receive 2 more cycles.&#xD;
&#xD;
      DOX: Docetaxel 35 mg/m2 day 1 and 8 Oxaliplatin 80 mg/m2 day 1 Capecitabine 750 mg/m2 x 2&#xD;
      daily for 2 weeks&#xD;
&#xD;
      Cycles repeated every 3 weeks&#xD;
&#xD;
      Evaluation criteria: Tumor assessment will be performed according to the RECIST criteria&#xD;
      (version 1.1).&#xD;
&#xD;
      Duration of Study:&#xD;
&#xD;
      Overall study duration: 07/2010- 03/2017 Planned study duration per patient: 5 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference in percentage of patients receiving all the planned chemotherapeutic cycles between the two arms.</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of tumors downstaged at the diagnosis</measure>
    <time_frame>7 years</time_frame>
    <description>To determine the percentage of tumors downstaged at the diagnosis, compared with the pathological stage detected at the time of surgery (according to Recist criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment tolerability and safety and tumor response in patients with pathological stage pT1-3 vs pT0</measure>
    <time_frame>7 years</time_frame>
    <description>Comparation of treatment tolerability and safety and tumor response between patients with pathological stage pT1-3 vs pT0 (detected at the time of surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events of grade 3-4 as a measure of safety and tolerability</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic capability of PET</measure>
    <time_frame>7 years</time_frame>
    <description>Evaluation of the role of PET as a tool to detect tumor response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy comparation between curative vs palliative surgery</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic capability of CT scan, CT/PET and laparoscopy</measure>
    <time_frame>7 years</time_frame>
    <description>Evaluation of possible correlations between the diagnostic techniques CT scan, CT/PET and laparoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological profile of treatment toxicity</measure>
    <time_frame>7 years</time_frame>
    <description>Biological detection of molecular markers related to treatment toxicity (DPYD, MTHFR, TS, XPD, ERCC1, XRCC1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological profile of treatment prognosis</measure>
    <time_frame>7 years</time_frame>
    <description>Biological detection of molecular markers related to treatment prognosis (TYMS, GSTP1, COX-2, RUNX3, methylation profile (Cox2, hMLH1, MGMT))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologcal profile of treatment response</measure>
    <time_frame>7 years</time_frame>
    <description>Biological detection of molecular markers related to therapy response (TYMS, DPYD, MTHFR, OPRT, ERCC1, XRCC1/2/3, GSTP1, GSTM1, GSTT1, ABCB1, methylation profile (Cox2, hMLH1, MGMT), whole genome arrayCGH)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DOX 4 cycles - Surgery - Follow-up&#xD;
DOX:&#xD;
Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.&#xD;
Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up&#xD;
DOX:&#xD;
Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.&#xD;
Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.&#xD;
Each cycle will be repeated every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DOX 4 cycles - Surgery</intervention_name>
    <description>DOX 4 cycles - Surgery</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DOX 2 cycles - Surgery - DOX 2 cycles</intervention_name>
    <description>DOX 2 cycles - Surgery - DOX 2 cycles</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consents&#xD;
&#xD;
          2. Male or female 18-75 years of age&#xD;
&#xD;
          3. Diagnosis of histologically confirmed, potentially resectable adenocarcinoma of the&#xD;
             stomach&#xD;
&#xD;
          4. cT3 subserosal - cT4a - cT4b (7th edition UICC TNM) or bulky lymph node metastases&#xD;
             independently of T&#xD;
&#xD;
          5. ECOG performance status of 0-1 at study entry&#xD;
&#xD;
          6. Laboratory requirements (≤ 7 days prior chemotherapy start):&#xD;
&#xD;
               1. Hematology:&#xD;
&#xD;
                  I) Neutrophils &gt; 1.5 x 109 /L II) Platelets &gt; 100 x 109 /L III) Hemoglobin &gt;&#xD;
                  10g/dL&#xD;
&#xD;
               2. Hepatic function I) Total bilirubin &lt; 1.25 UNL II) AST (SGOT) and ALT (SGPT) &lt;&#xD;
                  2.5xUNL III) Alkaline phosphatase &lt; 2.5xUNL&#xD;
&#xD;
               3. Renal function I) Creatinine &lt;1.5 UNL In the event of border-line values, the&#xD;
                  calculated creatinine clearance should be &gt; 60 mL/min;&#xD;
&#xD;
                    -  Written informed consent signed and dated before randomization procedures,&#xD;
                       including expected cooperation of patients for treatment and follow-up, must&#xD;
                       be obtained and documented according to local regulatory requirements.&#xD;
&#xD;
                    -  Effective contraception for both male and female patients if the risk of&#xD;
                       conception exists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Early gastric cancer (if N0)&#xD;
&#xD;
          2. T2 (according to 7th edition of UICC TNM) if N0&#xD;
&#xD;
          3. Linitis plastica&#xD;
&#xD;
          4. Positive peritoneal cytology&#xD;
&#xD;
          5. Distant metastases&#xD;
&#xD;
          6. Neoplasm involving the gastro-esophageal junction&#xD;
&#xD;
          7. Pertoneal involvement&#xD;
&#xD;
          8. Concurrent chronic systemic immune therapy&#xD;
&#xD;
          9. Any investigational agent(s) administered 4 weeks prior to entry&#xD;
&#xD;
         10. Clinically relevant coronary artery disease, a history of myocardial infarction or of&#xD;
             hypertension not controlled by therapy within the last 12 months&#xD;
&#xD;
         11. Known grade 3 or 4 allergic reaction to any of the components of the treatment&#xD;
&#xD;
         12. Known drug abuse/alcohol abuse&#xD;
&#xD;
         13. Legal incapacity or limited legal capacity&#xD;
&#xD;
         14. Medical or psychological condition which, in the opinion of the investigator, would&#xD;
             not permit the patient to complete the study or sign meaningful informed consent&#xD;
&#xD;
         15. Women who are pregnant or breastfeeding&#xD;
&#xD;
         16. Acute or subacute intestinal occlusion&#xD;
&#xD;
         17. Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of&#xD;
             the cervix. (Patients with a previous malignancy but without evidence of disease for ≥&#xD;
             5 years will be allowed to enter the trial)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manlio Monti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRST IRCCS, Meldola</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - GM Lancisi</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USL 8 Arezzo - Presidio Ospedaliero Zona Casentino - Ospedale di Bibbiena</name>
      <address>
        <city>Bibbiena</city>
        <state>AR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USL 8 Arezzo - Ospedale &quot;Santa Maria alla Gruccia&quot;</name>
      <address>
        <city>Valdarno (Montevarchi)</city>
        <state>AR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia , Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bufalini</name>
      <address>
        <city>Cesena</city>
        <state>FC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO oncologia medica IRCCS IRST</name>
      <address>
        <city>Meldola (FC)</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia , Azienda USL 11</name>
      <address>
        <city>Empoli</city>
        <state>FI</state>
        <zip>50053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO ONCOLOGIA , Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia, Fondazione Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia Medica, PO Rimini, AUSL della Romagna</name>
      <address>
        <city>Rimini</city>
        <state>RI</state>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia , Casa di Cura Tortorella</name>
      <address>
        <city>Salerno</city>
        <state>SA</state>
        <zip>84122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Le Scotte</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia, Azienda Ospedaliero Treviglio</name>
      <address>
        <city>Treviglio</city>
        <state>TV</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia Medica, azienda Ospedaliera di Varese</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Filippo Neri</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Borgo Trento</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2013</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally</keyword>
  <keyword>Advanced</keyword>
  <keyword>Resectable</keyword>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

